Zobrazeno 1 - 3
of 3
pro vyhledávání: '"for the IMI-EPAD collaborators"'
Autor:
Lisa Vermunt, Graciela Muniz-Terrera, Lea ter Meulen, Colin Veal, Kaj Blennow, Archie Campbell, Isabelle Carrié, Julien Delrieu, Karine Fauria, Gema Huesa Rodríguez, Silvia Ingala, Natalie Jenkins, José Luis Molinuevo, Pierre-Jean Ousset, David Porteous, Niels D. Prins, Alina Solomon, Brian D. Tom, Henrik Zetterberg, Marissa Zwan, Craig W. Ritchie, Philip Scheltens, Gerald Luscan, Anthony J. Brookes, Pieter Jelle Visser, for the IMI-EPAD collaborators
Publikováno v:
Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-10 (2020)
Abstract Background Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD). Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD pathology in individuals witho
Externí odkaz:
https://doaj.org/article/26daa0d3187e4841a7a7fa420c1cad83
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Vermunt, Lisa, Muniz-Terrera, Graciela, Ter Meulen, Lea, Veal, Colin, Blennow, Kaj, Campbell, Archie, Carrié, Isabelle, Delrieu, Julien, Fauria, Karine, Huesa Rodríguez, Gema, Ingala, Silvia, Jenkins, Natalie, Molinuevo, José Luis, Ousset, Pierre-Jean, Porteous, David, Prins, Niels D, Solomon, Alina, Tom, Brian D, Zetterberg, Henrik, Zwan, Marissa, Ritchie, Craig W, Scheltens, Philip, Luscan, Gerald, Brookes, Anthony J, Visser, Pieter Jelle, IMI-EPAD Collaborators
BACKGROUND: Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD). Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD pathology in individuals without demen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62ce408db64f5fec273bd6b7fb0b5338
